Strategic Expansion for Quotient Clinical

Quotient Clinical, a business unit of leading drug development services provider Quotient Bioresearch, has announced the completion of a major expansion of its Pharmaceutical Sciences facilities in Nottingham, UK. The GMP manufacturing suite has doubled in size and now incorporates six independent manufacturing rooms supporting oral, inhaled and parenteral drug products. The formulation development and pharmaceutical analysis laboratory areas have also been significantly increased and now occupy an 11,000ft2 purpose-built facility. The new facilities have been inspected and approved for use by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), and are now fully operational.

The expansion is a response to the increasing demand for the company’s RapidFACT™ service which provides investigation and optimisation of new drug product formulations in humans. Mark Egerton, MD Quotient Clinical, commented: “Following the recent announcement of our collaboration agreement with Bend Research, the completion of our Pharmaceutical Sciences laboratory and GMP expansion is a milestone achievement, representing a further significant investment in our RapidFACT service. The extended capabilities and capacity will be invaluable in underpinning RapidFACT and cementing its position as a key tool in the early drug development process.”